Profound Sinoatrial Arrest Associated with Ibrutinib

BACKGROUND: Ibrutinib is a Bruton's tyrosine kinase (BTK) inhibitor approved for second-line treatment for mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), and Waldenström macroglobulinemia. Ibrutinib use has been linked to increased incidence of atrial fibrillation and hypertens...

Descripción completa

Detalles Bibliográficos
Autores principales: Mathur, Kanupriya, Saini, Aditya, Ellenbogen, Kenneth A., Shepard, Richard K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5742500/
https://www.ncbi.nlm.nih.gov/pubmed/29375920
http://dx.doi.org/10.1155/2017/7304021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5742500/
https://www.ncbi.nlm.nih.gov/pubmed/29375920
http://dx.doi.org/10.1155/2017/7304021

Ejemplares similares